Source comparison
BPC-157 vs Cortisone Injections: Clinical Comparison
Mechanism Suppresses inflammatory cytokines (IL-1, IL-6, TNF-alpha) by binding glucocorticoid receptors Upregulates VEGF and bFGF to promote angiogenesis, fibroblast migration, and collagen synthesis Cortisone stops inflammation; BPC-157 accelerates repair Ons
This comparison does not assign a generated winner or score.
- Mechanism
- Suppresses inflammatory cytokines (IL-1, IL-6, TNF-alpha) by binding glucocorticoid receptors
- Upregulates VEGF and bFGF to promote angiogenesis, fibroblast migration, and collagen synthesis
- Cortisone stops inflammation; BPC-157 accelerates repair
- Onset of Effect
- 24–72 hours (symptom relief)
- 7–14 days (structural improvement)
- Cortisone is faster for pain; BPC-157 requires patience
- Duration of Effect
- 2 weeks – 3 months (depends on corticosteroid half-life)
- Gradual improvement over 4–8 weeks; benefits persist post-treatment
- Cortisone wears off; BPC-157 builds cumulative healing
- Tissue Impact
- Inhibits collagen synthesis; repeated use weakens tendons and increases rupture risk 3.7-fold
- Increases collagen I/III deposition; no documented tissue weakening
- Cortisone degrades tissue long-term; BPC-157 strengthens it
- Regulatory Status
- FDA-approved for medical use since 1950s; covered by insurance
- Research peptide; not FDA-approved; available through compounding pharmacies
- Cortisone is standard-of-care; BPC-157 is experimental
- Cost
- $50–$200 per injection (often insurance-covered)
- $150–$400 per vial (4–8 week supply); not insurance-covered
- Cortisone is cheaper upfront; BPC-157 costs more out-of-pocket